1. [A comparative study between cefpirome (CPR) and ceftazidime (CAZ) in respiratory tract infections]
- Author
-
Rinzo SOEJIMA, Masaru SUMI, Jiro HINO, Niro OKIMOTO, Yoshikazu KAWAKAMI, Etsuro YAMAGUCHI, Tsugio TERAI, Takashi YOSHIKAWA, Kazuo TAKAOKA, Akira SAITO, Masumi TOMIZAWA, Ichiro NAKAYAMA, Hidetoshi SHIBAKI, Koji TANEICHI, Tsuyoshi KIKUIRI, Masahide SHINOHARA, Akira MIWA, Choei ITO, Mitsuo SATO, Akira SUZUKI, Yasuhito HONDA, Kyuichiro SEKINE, Yomei HIRAGA, Mitsuhide OMICHI, Shinya YASUDA, Tetsuji KOROKU, Susumu ITO, Shoji KASAGI, Sokichi ONODERA, Yoshinobu OSAKI, Hiroyuki MATSUMOTO, Takafumi OTA, Eiichi SAKAI, Tetsuo SHIMIZU, Nobuhiro SASAKI, Toshiaki FUJIKANE, Satoshi FUJIUCHI, Toshiaki SHISHIDO, Kazuo TAKEBE, Atsuko YANADA, Mitsuo MASUDA, Seiichi MURAKAMI, Kenichi IMAMURA, Toyokazu TAMURA, Katsumi ENDO, Hideya MURABAYASHI, Shigeru OCHIAI, Hidekazu SAWADA, Michitaka SHIMURA, Masashi TAMURA, Kazuki KONISHI, Taiji YOSHIDA, Morio SUDO, Takeshi BANDO, Nobuhisa SATO, Masayuki OURA, Tetsuro UNOURA, Takashi MOURI, Tamotsu TAKISHIMA, Yasuo TANNO, Kunio KUDO, Munehiko ISHII, Masaharu SUGIYAMA, Masakichi MOTOMIYA, Akira WATANABE, Kosaku NAGAI, Kazuo SATO, Kiyoshi KONNO, Teruo HASUIKE, Kuniharu SHIDA, Satoshi SHINDO, Izumi HAYASHI, Jingoro SHIMADA, Masaki YOSHIDA, Atsushi SAITO, Koya SHIBA, Masanobu KAJI, Seiji HORI, Osamu SAKAI, Hideo MIYASHITA, Yasuo ONO, Masumi BABA, Hiroyuki KOBAYASHI, Hiroshi OSHITANI, Hiroshi MIURA, Takashi INOUE, Kaoru SHIMADA, Mieko GOTO, Hajime GOTO, Yasuyuki SANO, Yasufumi MIYAMOTO, Yasuo ARAI, Kanzaburo MATSUMURA, Yoshitaka NAKAMORI, Koji NARUI, Masayuki NOGUCHI, Tatsuo NAKATANI, Koichiro NAKATA, Iwao SAKURAI, Takeo IMAI, Fumio MATSUMOTO, Shigeki ODAGIRI, Masanori MATSUMURA, Kaneo SUZUKI, Kou MUROHASHI, Hiroshi TAKAHASHI, Kenichi TAKAHASHI, Teruaki YOSHIOKA, Izumi KOYAMA, Takashi OGURA, Masaaki ARAKAWA, Koichi WADA, Takashi KAWASHIMA, Masanaga TAKATO, Hidenori KUMANO, Nobuki AOKI, Tatsuo SATAKE, Kenichi YAMAKI, Ryujiro SUZUKI, Kenzo TAKAGI, Hitoshi TANAKA, Masatoshi IMAI, Toshiaki TSUNODA, Yoshiaki WATANABE, Toshihiko TAKEUCHI, Yoshimitsu HAYASHI, Kazuhide YAMAMOTO, Yasuo YAMADA, Fumiyuki KUZE, Takako MURAYAMA, Katsuhiro SUZUKI, Motokazu KATO, Masaru CHIBA, Riyo YAMAGUCHI, Hitoshi NAGAI, Fumikazu UMEDA, Hiromi TOMIOKA, Osamu EBISUI, Hironobu IWASAKI, Kenji BANDO, Takashi NISHIMURA, Tatsuki OYAIZU, Sunao ISHIDA, Shunsaku OHSHIMA, Masao KADO, Hirotaka YASUBA, Kikuo SUGIMOTO, Seibun YONEZU, Yoshihiro UEDA, Kojiro YASUNAGA, Fumio MIKI, Eiro TSUBURA, Masaru NAKAGAWA, Takeshi OGURA, Fumitaka OGUSHI, Masashi KAWANISHI, Waka ICHIKAWA, Kazuhito MIZUNO, Seiko ISHIKAWA, Yoshihiro TAKISHITA, Hiroyasu BANDO, Yoshihiro HASHIMOTO, Nobuhiro NARITA, Masayoshi SAWAKI, Keiichi MIKASA, Mitsuru KONISHI, Toshiharu MATSUSHIMA, Makoto KIMURA, Masayasu KAWANISHI, Tadasu KURIMURA, Hideo SASAKI, Hirofumi FUKUHARA, Takao SASAKI, Yukio MATSUMOTO, Yuji SUGIMOTO, Yoshiro SAWAE, Toshiyuki ISHIMARU, Koji TAKAGI, Nobuyuki SHIMONO, Nobuaki SHIGEMATSU, Katsuro YAGAWA, Shinichiro HAYASHI, Kenji KONO, Keisuke ONUKI, Shinichi TOHARA, Seiji TAKEDA, Masahide TAKII, Katsumi OKUDAIRA, Akihiko SAKAUE, Koichi SHINOHARA, Kotaro OIZUMI, Yoichiro ICHIKAWA, Masashi KAWAHARA, Kohei HARA, Masaki HIROTA, Keizo YAMAGUCHI, Shigeru KONO, Hironobu KOGA, Mitsuo KAKU, Yasumasa DOTSU, Hiroshi YAMADA, Kiyoyasu FUKUSHIMA, Naofumi SUYAMA, Toshiaki HAYASHI, Keizo MATSUMOTO, Toshiaki YOSHIDA, Tsuyoshi NAGATAKE, Moritoshi AKIYAMA, Masakazu TAKASUGI, Mikio TAGUCHI, Kiwao WATANABE, Harumi SHISHIDO, Kiyoshi SHIMA, Shinobu TAKENAKA, Masaru NASU, Jun GOTO, Hideaki SHIGENO, Yoichiro GOTO, Takayoshi TASHIRO, Hiroyuki NAGAI, Toru YAMAZAKI, Mitsunobu AKASHI, Hiroshi FUKUHARA, Hiroshi KANESHIMA, Yuei IRABU, Katsuyoshi SHIMOJI, Keizo KITSUKAWA, Yoshiteru SHIGENO, and Nobuya OGAWA
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,education ,Ceftazidime ,CEFPIROME SULFATE ,medicine ,Humans ,In patient ,Clinical efficacy ,Intensive care medicine ,Respiratory Tract Infections ,Aged ,Aged, 80 and over ,Respiratory tract infections ,business.industry ,Significant difference ,General Medicine ,Cefpirome ,Middle Aged ,Cephalosporins ,Clinical trial ,Anesthesia ,Female ,business ,medicine.drug - Abstract
Efficacy and safety of a new injectable cephem antibiotic, cefpirome sulfate (hereafter, CPR), against respiratory tract infections were examined and compared with those of a control drug, ceftazidime (hereafter, CAZ). As a rule, CPR 0.5 g twice a day, 1.0 g twice a day, or CAZ 1.0 g twice a day (hereafter CPR 0.5 g group, CPR 1.0 g group, and CAZ group) was administered for 14 days and the following results were obtained. 1. The total number of cases was 470 (155 cases in the CPR 0.5 g group, 160 cases in the CPR 1.0 g group, and 155 cases in the CAZ group). Among them 390 cases were subjected to analyses of clinical efficacy by the efficacy evaluation committee (131 cases in the CPR 0.5 g group, 131 cases in the CPR 1.0 g group and 128 cases in the CAZ group). 2. Efficacy rates determined by the efficacy evaluation committee were 82.4% (108/131) for the CPR 0.5 g group, 81.7% (107/131) for the CPR 1.0 g group, and 83.6% (107/128) for the CAZ group. Efficacy rates determined by the physician in charge were 82.0% (105/128) for the CPR 0.5 g group, 80.5% (99/123) for the CPR 1.0 g group, and 88.5% (108/122) for the CAZ group. No statistically significant difference was observed among the 3 groups. In evaluation of equivalency, clinical efficacy for the CPR 0.5 g group and the CPR 1.0 g group determined by the clinical efficacy evaluation committee was proved to be statistically equivalent to that for the CAZ group. 3. In patients with pneumonia, efficacy rates determined by the efficacy evaluation committee were 87.1% (61/70) for the CPR 0.5 g group, 80.7% (71/88) for the CPR 1.0 g group, and 78.9% (56/71) for the CAZ group. Efficacy rates determined by the physician in charge were 85.3% (58/68) for the CPR 0.5 g group, 80.7% (67/83) for the CPR 1.0 g group, and 86.2% (56/65) for the CAZ group and no statistically significant difference was observed among the 3 groups. In patients with chronic respiratory tract infection, efficacy rates determined by the efficacy evaluation committee were 77.0% (47/61) for the CPR 0.5 g group, 83.7% (36/43) for the CPR 1.0 g group, and 89.5% (51/57) for the CAZ group. Efficacy rates determined by the physician in charge were 78.3% (47/60) for the CPR 0.5 g group, 80.0% (32/40) for the CPR 1.0 g group, and 91.2% (52/57) for the CAZ group. No statistically significant difference was observed among the 3 groups.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1991